Beneficial metabolites

Beneficial metabolites" is not the name of a specific molecule, protein, or receptor. Instead, it is a broad descriptive term referring to small molecules produced by living organisms—most commonly by gut microbiota—that exert positive effects on host physiology. These include short-chain fatty acids such as butyrate, acetate, and propionate; secondary bile acids; vitamins; and other bioactive compounds. Such metabolites can serve as energy sources for intestinal epithelial cells, modulate immune responses, maintain the integrity of the gut barrier, and protect against pathogens or inflammation[2][3][4]. The term does not refer to a single molecular entity or therapeutic target but rather encompasses a diverse group of compounds with various biological activities. Because "beneficial metabolites" is not a canonical molecular target—such as an enzyme, receptor, transporter—it should not be considered an individual drug target. Instead, it describes functional classes of molecules that may act through multiple targets including G-protein-coupled receptors (e.g., SCFA receptors), nuclear hormone receptors (e.g., FXR for bile acids), or direct metabolic effects on host tissues[2][3][4]. Therefore: There is something wrong with this target: It is too broad/vague to be used as a canonical drug discovery target name. For structured data purposes in pharmacology or drug development databases, each specific metabolite should be listed individually under its proper chemical/molecular name and classification. If you need information about specific beneficial microbial metabolites such as "butyrate," "propionate," "secondary bile acid," etc., those would each have their own entries with detailed structured information.

Other names

Beneficial metabolitesMicrobiota-derived beneficial metabolitesGut microbial metabolites